Status: Not yet recruiting
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors
Participants needed: 219
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: TYK Medicines, IncUpdated: Dec 22, 2025Locations: 1
Eligibility criteria
Male or female subjects ≥18 years old [+7]
Presence of pleural effusion, pericardial effusion, or ascites that, in the inve... [+6]